Why has the survival of patients with bladder cancer not improved?

BJU International

Volumn 101, Issue 3, 2008, Pages 267-269

  Malmström, Per Uno ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN;

BLADDER CANCER; BLADDER PRESSURE; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER PATIENT; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CYSTECTOMY; CYSTOSCOPY; FGFR 3 GENE; FLUORESCENCE; HUMAN; LYMPH NODE METASTASIS; MINIMALLY INVASIVE SURGERY; NONHUMAN; NOTE; ONCOGENE H RAS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROGNOSIS; RECEPTOR GENE; RECURRENCE RISK; TRANSURETHRAL RESECTION; TREATMENT INDICATION;

COMBINED MODALITY THERAPY; DISEASE PROGRESSION; HUMANS; NEOPLASM INVASIVENESS; SURVIVAL ANALYSIS; URINARY BLADDER NEOPLASMS;

EID: 37849025502     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.07308.x     Document Type: Note

References (23)

1. Lambert EH, Pierorazio PM, Olsson CA, Benson MC, McKiernan JM, Poon S. The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy. BJU Int 2007 100 : 33 6
2. Araki M, Nieder AM, Manoharan M, Yang Y, Soloway MS. Lack of progress in early diagnosis of bladder cancer. Urology 2007 69 : 270 4
3. Malmstrom PU, Thorn M, Lindblad P, Bergstrom R, Adami HO. Increasing survival of patients with urinary bladder cancer. A nationwide study in Sweden 1960-86. Eur J Cancer 1993 29A : 1868 72
4. Gardmark T, Bladstrom A, Hellsten S, Malmstrom PU, Members of The Swedish National Bladder Cancer Registry. Analysis of clinical characteristics, management and survival of patients with Ta T1 bladder tumours in Sweden between 1997 and 2001. Scand J Urol Nephrol 2006 4 : 276 82
5. Sant M, Aareleid T, Berrino F et al. EUROCARE-3: survival of cancer patients diagnosed 1990-94 - results and commentary. Ann Oncol 2003 14 : 61 118
6. Soloway MS, Masters S. Urothelial susceptibility to tumor cell implantation influence of cauterization. Cancer 1980 46 : 1158 63
7. El-Abbady AA, Shoukry MS, Hanno AG et al. Repeated transurethral resection of recurrent superficial bladder tumors - does it affect the spread and stage of the tumor? Scand J Urol Nephrol 2002 36 : 60 4
8. Schrier BP, Hollander MP, van Rhijn BW, Kiemeney LA, Witjes JA. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol 2004 45 : 292 6
9. Hellsten S, Glifberg I, Lindholm CE, Telhammar E. Therapy of bladder carcinoma. Long-term results of a retrospective study of 214 cases. Scand J Urol Nephrol 1981 15 : 115 20
10. Beisland HO, Seland P. A prospective randomized study on neodymium-YAG laser irradiation versus TUR in the treatment of urinary bladder cancer. Scand J Urol Nephrol 1986 20 : 209 12
11. Hartmann A, Rösner U, Schlake G et al. Clonality and genetic divergence in multifocal low-grade superficial urothelial carcinoma as determined by chromosome 9 and p53 deletion analysis. Lab Invest 2000 80 : 709 18
12. Schultz IJ, Wester K, Straatman H et al. Prediction of recurrence in Ta urothelial cell carcinoma by real-time quantitative PCR analysis: a microarray validation study. Int J Cancer 2006 119 : 1915 9
13. van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH, Zwarthoff EC. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 2001 61 : 1265 8
14. Knowles MA. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis 2006 27 : 361 73
15. Jordan AM, Weingarten J, Murphy WM. Transitional cell neoplasms of the urinary bladder. Can biologic potential be predicted from histologic grading? Cancer 1987 60 : 2766 74
16. Heney NM, Ahmed S, Flanagan MJ et al. Superficial bladder cancer: progression and recurrence. J Urol 1983 130 : 1083 6
17. Cappellen D, De Oliveira C, Ricol D et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999 23 : 18 20
18. Holmäng S, Andius P, Hedelin H, Wester K, Busch C, Johansson SL. Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. J Urol 2001 165 : 1124 8
19. Prout GR Jr., Griffin PP, Shipley WU. Bladder carcinoma as a systemic disease. Cancer 1979 43 : 2532 9
20. Liedberg F, Månsson W. Lymph node metastasis in bladder cancer. Eur Urol 2006 49 : 13 21
21. Advanced Bladder Cancer Overview Collaboration. Neoadjuvant chemotherapy for invasive bladder cancer. Cochrane Database Syst Rev 2005 2 CD005246
22. Olaussen KA, Dunant A, Fouret P et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006 355 : 983 91
23. Bellmunt J, Paz-Ares L, Cuello M et al. Spanish Oncology Genitourinary Group. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 2007 18 : 522 8